TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,834.65−0.29%FTSE ADX9,829.37+0.47%TASI9,952.06−1.69%QE Index8,598.42−0.40%S&P 5007,710.66+0.26%Nasdaq 10029,526.04−0.01%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,151.64−0.49%DFM:EMIRATESNBDAED 31.58+0.25%ADX:IHCAED 356.60+1.31%SAU:2222SAR 25.48−1.24%DSMD:QNBKQAR 15.55−0.70%NAS:NVDA$216.86−0.11%NYSE:TSM$426.94+1.60%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 300.01+0.18%Gold$4,121.71−0.46%Brent$108.99−0.21%BTC$82,637.24+0.97%ETH$2,446.41+1.71%DFM General5,834.65−0.29%FTSE ADX9,829.37+0.47%TASI9,952.06−1.69%QE Index8,598.42−0.40%S&P 5007,710.66+0.26%Nasdaq 10029,526.04−0.01%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100165,151.64−0.49%DFM:EMIRATESNBDAED 31.58+0.25%ADX:IHCAED 356.60+1.31%SAU:2222SAR 25.48−1.24%DSMD:QNBKQAR 15.55−0.70%NAS:NVDA$216.86−0.11%NYSE:TSM$426.94+1.60%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 300.01+0.18%Gold$4,121.71−0.46%Brent$108.99−0.21%BTC$82,637.24+0.97%ETH$2,446.41+1.71%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Open 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Closed

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Aardvark Therapeutics Inc · Overview · TradingHolo

Markets › United States › NAS › AARD

A

Aardvark Therapeutics Inc

NAS:AARDHealthcareNASDAQ:NBInasdaq_composite

$3.78−2.07%At closeAt close · Sat 17 Oct · ≈ AED 13.88 · Market cap $82.72M · Next earnings Thu 12 Nov

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

1D

−2.1%

1M

−31.6%

3M

−31.6%

6M

−27.7%

1Y

−72.9%

Why it's moving today

Aardvark Therapeutics Price Target Cut to $4.00/Share From $6.00 by HC Wainwright & Co.

Dow Jones Newswires · Mon 19 Oct

✦ This week in three lines

No written digest yet for AARD. The figures on this page are the source when one is written.

Financials

USD millions · annual3Y CAGR —

Valuation

P/E vs sector−1.4× vs −1.7×

Price / Book vs sector0.8× vs 2.0×

Price / Sales vs sector—

Price / Free cash flow vs sector−1.5× vs −1.6×

Forecasts

5 buy3 hold2 sell10 analysts

Average target$0.0000 −100.0%

Analysts0

EPS surprises, last 73 beats

Dividends

Yield0.0%

Annual payout—

Payout ratio0.0%

Next ex-date—

Years of growth—

Latest news

All AARD news →

DOAardvark Therapeutics Price Target Cut to $4.00/Share From $6.00 by HC Wainwright & Co.

Dow Jones Newswires · 30 h ago

TRHC Wainwright & Co. maintains Neutral rating on Aardvark Therapeutics, $4 price target

TradingView · 30 h ago

TRDavid (Zhongwei) Zhang appointed to Aard board as Class II director

TradingView · 12 d ago

Key facts

At close · Sat 17 Oct

Market cap (USD)$82.72M

P/E−1.4×

Dividend yield0.0%

52-week range$3.35 – $16.60

Avg volume (20d)117,600

Shares outstanding21,884,846

Beta3.81

Short interest3.7% of float

Next earningsThu 12 Nov

Radar Score

40

Value52

Quality40

Momentum24

Income45

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary…

SectorHealthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

57.3×+0.43%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

23.0×+0.90%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

119.3×+0.71%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

29.9×−1.29%